Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 1
2007 5
2008 7
2009 8
2010 6
2011 12
2012 8
2013 15
2014 21
2015 12
2016 14
2017 13
2018 19
2019 26
2020 24
2021 46
2022 47
2023 36
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

315 results

Results by year

Filters applied: . Clear all
Page 1
A comparison of mobilization and mobilization with movement on pain and range of motion in people with lateral ankle sprain: A randomized clinical trial.
Norouzi A, Delkhoush CT, Mirmohammadkhani M, Bagheri R. Norouzi A, et al. J Bodyw Mov Ther. 2021 Jul;27:654-660. doi: 10.1016/j.jbmt.2021.05.006. Epub 2021 May 16. J Bodyw Mov Ther. 2021. PMID: 34391302 Clinical Trial.
RESULTS: There were no significant differences between the two groups in terms of pain (P = 0.297) and range of motion (P = 0.294) before the intervention. Meanwhile, after the intervention, a significant change was observed in both groups in terms of these variable …
RESULTS: There were no significant differences between the two groups in terms of pain (P = 0.297) and range of motion (P = 0. …
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. WHO Solidarity Trial Consortium, et al. N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2. N Engl J Med. 2021. PMID: 33264556 Free PMC article. Clinical Trial.
Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P = 0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its control (rate r …
Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence inter …
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
WHO Solidarity Trial Consortium. WHO Solidarity Trial Consortium. Lancet. 2022 May 21;399(10339):1941-1953. doi: 10.1016/S0140-6736(22)00519-0. Epub 2022 May 2. Lancet. 2022. PMID: 35512728 Free PMC article.
Of those not ventilated but on oxygen, 14.6% assigned to remdesivir died versus 16.3% assigned to control (RR 0.87 [0.76-0.99], p=0.03). Of 1730 not on oxygen initially, 2.9% assigned to remdesivir died versus 3.8% assigned to control (RR 0.76 [0.46-1.28], p=0.30). …
Of those not ventilated but on oxygen, 14.6% assigned to remdesivir died versus 16.3% assigned to control (RR 0.87 [0.76-0.99], p=0.0 …
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell BCV, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Coutts SB, et al. Lancet. 2024 Jun 15;403(10444):2597-2605. doi: 10.1016/S0140-6736(24)00921-8. Epub 2024 May 17. Lancet. 2024. PMID: 38768626 Clinical Trial.
The primary outcome occurred in 338 (75%) of 452 patients in the control group and 309 (72%) of 432 in the tenecteplase group (risk ratio [RR] 0.96, 95% CI 0.88-1.04, p=0.29). More patients died in the tenecteplase group (20 deaths [5%]) than in the control group (five dea …
The primary outcome occurred in 338 (75%) of 452 patients in the control group and 309 (72%) of 432 in the tenecteplase group (risk ratio [R …
Crosstalk in cancer resistance and metastasis.
Norouzi S, Gorgi Valokala M, Mosaffa F, Zirak MR, Zamani P, Behravan J. Norouzi S, et al. Crit Rev Oncol Hematol. 2018 Dec;132:145-153. doi: 10.1016/j.critrevonc.2018.09.017. Epub 2018 Oct 4. Crit Rev Oncol Hematol. 2018. PMID: 30447920 Review.
Therefore, devising and application of chemotherapeutic procedures that are not prone to the development of chemotherapy resistance are necessary. Here, we focus on CD147, CD44, ANAX2, P-gp, MMPs, and UCH-L1 proteins involved in the crosstalk between metastasis and cancer …
Therefore, devising and application of chemotherapeutic procedures that are not prone to the development of chemotherapy resistance are nece …
Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study.
COVIDSurg Collaborative; GlobalSurg Collaborative. COVIDSurg Collaborative, et al. Anaesthesia. 2021 Nov;76(11):1454-1464. doi: 10.1111/anae.15560. Epub 2021 Aug 9. Anaesthesia. 2021. PMID: 34371522 Free article. Clinical Trial.
Although the overall rates of postoperative pulmonary complications were similar in those that isolated and those that did not (2.1% vs 2.0%, respectively), isolation was associated with higher rates of postoperative pulmonary complications after adjustment (adjusted OR 1.20, 95% …
Although the overall rates of postoperative pulmonary complications were similar in those that isolated and those that did not (2.1% vs 2.0% …
Effects of L-Carnitine and Coenzyme Q10 Supplementation on Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia: A Randomized, Controlled, Clinical Trial.
Norouzi M, Mahboobi S, Eftekhari MH, Salehipour M, Ghaem H, Mirzakhanlouei A, Mohsenpour MA. Norouzi M, et al. Nutr Cancer. 2024;76(2):207-214. doi: 10.1080/01635581.2023.2295578. Epub 2024 Jan 18. Nutr Cancer. 2024. PMID: 38105612 Clinical Trial.

Supplementation with LC and CoQ10 led to a significant decrease in prostate volume (p < 0.001) as well as a significant increase in IIEF (p < 0.001), compared to the control group. However, there were no significant between-group differences in IPSS (p

…

Supplementation with LC and CoQ10 led to a significant decrease in prostate volume (p < 0.001) as well as a significant increase i

…
Anticancer peptides mechanisms, simple and complex.
Norouzi P, Mirmohammadi M, Houshdar Tehrani MH. Norouzi P, et al. Chem Biol Interact. 2022 Dec 1;368:110194. doi: 10.1016/j.cbi.2022.110194. Epub 2022 Oct 1. Chem Biol Interact. 2022. PMID: 36195187 Review.
An Updated Review of Various Medicinal Applications of p-Co umaric Acid: From Antioxidative and Anti-Inflammatory Properties to Effects on Cell Cycle and Proliferation.
Abazari MF, Nasiri N, Karizi SZ, Nejati F, Haghi-Aminjan H, Norouzi S, Piri P, Estakhr L, Faradonbeh DR, Kohandani M, Daliri K, Sanadgol N, Askari H. Abazari MF, et al. Mini Rev Med Chem. 2021;21(15):2187-2201. doi: 10.2174/1389557521666210114163024. Mini Rev Med Chem. 2021. PMID: 33459233 Review.
P-Coumaric acid (p-CA) is a hydroxycinnamic acid, an organic compound that is a hydroxyl derivative of cinnamic acid. ...Recently, the therapeutic properties of p-CA have received a great deal of attention from scientific society. Here, we described the medic …
P-Coumaric acid (p-CA) is a hydroxycinnamic acid, an organic compound that is a hydroxyl derivative of cinnamic acid. ...Recen …
Grey Zone: A Gap Between Heavy and Severe Exercise Domain.
Ozkaya O, Balci GA, As H, Cabuk R, Norouzi M. Ozkaya O, et al. J Strength Cond Res. 2022 Jan 1;36(1):113-120. doi: 10.1519/JSC.0000000000003427. J Strength Cond Res. 2022. PMID: 32149880
The results showed that work rate corresponding to CT (329.5 41.5 W) was significantly greater than that of the MLSS (269.5 38.5 W; p = 0.000), VT (279.6 33 W; p = 0.000), and CP (306.3 39.4 W; p = 0.000), and CP overestimated both VT and MLSS (p = 0.0 …
The results showed that work rate corresponding to CT (329.5 41.5 W) was significantly greater than that of the MLSS (269.5 38.5 W; p …
315 results